Tokyo (August 29, 2001) - An Eisai Co., Ltd. (President and CEO: Haruo Naito) subsidiary in the U.S. located in Houston, U.S., dealing with synthetic vitamin E production, sales of bulk chemicals, and pharmaceutical production machinery, Eisai U.S.A. Inc. (President: Yutaka Hasegawa), announced on August 28 the decision to discontinue operations at its synthetic vitamin E (Bayport) plant in Pasadena, Texas and sales of bulk chemicals in the U.S. Sales of the pharmaceutical production machinery will continue.
Production of synthetic vitamin E in Japan as well as bulk sales operations in Japan, Europe and Asia will continue. The decision by Eisai U.S.A. Inc. will not have an effect on Eisai's pharmaceutical operations in the U.S.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of over $2.9 billion in 2000 with approximately 14 percent of sales spent for research and development.